Loading…
← CockpitCompetitor Analysis › 6078.HK Hygeia Healthcare Holdings Co., Ltd.Open in the cockpit ↗

Hygeia Healthcare Holdings Co., Ltd.6078.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum leader 86
Mkt cap
$811M
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$2.07M
20-day average traded
Fwd P/E
10.4×
forward earnings
ROIC−WACC
-3.6 pp
WACC 9.0%
Hurdle
-18 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$10.66
1D0.0%
1W-1.3%
1M+10.9%
3M+10.0%
6M-2.6%
YTD-14.2%
1Y-19.5%
ATR %2.9%
52w lowhigh26.7% off high

What Hygeia Healthcare does

Employees: 7,906

Hygeia Healthcare at a glance

Size Hygeia Healthcare (6078.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $811M, the 632nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.66 on 18 Nov 2026.

Performance Over six months the shares fell 2.6%, against -7.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th highest of 19 in its peer set.

Growth Revenue grew 1.6% over the last twelve months (peer median +2.8%); the operating margin is 14.2% (peer median 5.0%).

Valuation It trades at 10.4× forward earnings against a peer median of 22.0× (3rd cheapest of 9).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.6 points below its cost of capital (9.0% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20266078.HK 101Peer median 92
Six months, rebased to 100: Hygeia Healthcare against the median of its 20 peers (local-currency closes).

Hygeia Healthcare financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$4.45BHK$4.35BHK$4.82BHK$4.50BHK$3.72B
Revenue growth—-10%+7%+21%—
Gross profitHK$1.15BHK$1.11BHK$1.34BHK$1.34BHK$1.14B
EBITDAHK$969MHK$930MHK$1.23BHK$1.14BHK$999M
Net incomeHK$203MHK$178MHK$649MHK$755MHK$554M
Free cash flowHK$540MHK$424MHK$12.2M-HK$246MHK$44.0M
Capital expenditureHK$455MHK$524MHK$667MHK$1.04BHK$706M
Total debtn/aHK$2.72BHK$2.97BHK$3.00BHK$1.45B

Quarterly statements and history in the cockpit →

Hygeia Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%COLLSUVEN688073RIGL002082603229SANOFIORIC300267GUDIRWD002349ARDX000411BLISSGVS6886210023906078.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Hygeia Healthcare is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×100×200×COLL688073RIGLSANOFIGUDIRWDARDX6886216078.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Hygeia Healthcare is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-25%0%25%COLL688073RIGL002082SANOFIGUD002349BLISSGVS0023906078.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Hygeia Healthcare is the large dot.

Hygeia Healthcare competitors and peer comparison

How Hygeia Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Hygeia Healthcare against its 20 peers (data as of 18 Nov 2026)
Measure6078.HKPeer medianRank in peer set
1-month return+10.9%-6.5%4th highest of 19
6-month return-2.6%-7.7%8th highest of 19
Distance from 52-week high-26.7%-34.8%5th highest of 19
Revenue growth (TTM)+1.6%+2.8%8th lowest of 19
Operating margin14.2%5.0%8th highest of 19
Forward P/E10.4×22.0×3rd cheapest of 9
Growth the price implies (Req g, 7 yrs)4.6%6.6%5th least demanding of 10
Growth delivered (Del g)+22.5%+10.1%2nd highest of 10
Hurdle (Req g minus delivered)-18.0 pp-5.1 pp3rd least demanding of 10
ROIC minus cost of capital-3.6 pp-1.9 pp7th lowest of 18
EV / EBITDA8.4×10.0×3rd cheapest of 7
Net debt / EBITDA1.8×-0.5×2nd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%n/an/an/a
Bide Pharmatech 688073.SSChina$801M+10%+10%19%24.3×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%10.8×1.5%+22.1%
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%19.6×16.3%-8.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%42.2×6.6%+17.7%
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%3.5×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%n/a-2.5%+2.6%
Ardelyx ARDXUnited States$784M-50%+18%-8%252.9×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%n/an/an/a
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%n/a33.9%+10.1%
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%n/a-3.8%-0.8%

Questions

Which companies are Hygeia Healthcare's closest peers?
The cockpit's peer set: Collegium Pharmaceutical (COLL), Suven Life Sciences (SUVEN.NS), Bide Pharmatech (688073.SS), Rigel Pharmaceuticals (RIGL), Wanbangde Pharmaceutical (002082.SZ), Zhejiang Ausun Pharmaceutical (603229.SS), Dezhan Healthcare (000813.SZ), Sanofi India (SANOFI.NS).
Is Hygeia Healthcare expensive compared with its peers?
On forward p/e it trades at 10.4× against a peer median of 22.0×, 3rd cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Hygeia Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned -2.6% against -7.7% for the median peer; over one year -19.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.